• How should we integrate multi-modal endpoints into IPF trial design without overcomplicating execution?
• What evidence is still needed for broader regulatory acceptance of imaging and novel endpoints?
• Are current endpoint strategies in IPF still fit for purpose in an era of combination therapies and smaller treatment effects?

Audience Feedback: Hear your industry peers thoughts on endpoint evolution